Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Fig. 4

The applications of in situ generation of CAR therapy in hematologic malignancies. (A) The Spleen SORT LNPs with CAR mRNA were utilized to produce CAR-T cells in situ, serving as a potential alternative for the treatment of B-cell lymphoma [84]; (B) PBAE-based NPs as safe and effective DNA delivery vectors, could deliver plasmids encoding CAR to produce CAR-T cells in situ for the anti-tumor immunotherapy of leukemia

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us